Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE. Dendreon noted that this new coverage of PROVENGE is now consistent with all other infused biologics.
The costs associated with administering PROVENGE will now be covered and can be billed separately. More importantly, the CMS decision will retroactively cover claims for costs associated with the administration of PROVENGE effective for dates on or after June 30, 2011. This now takes the average time to pay physicians to 30 days according to the company.
Dendreon shares are up over 8% at $9.03 in pre-market trading with about 55 minutes until the market opens and the 52-week trading range is $6.46 to $43.96.
JON C. OGG
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
